Natco Pharma Wins Approval to Manufacture Semaglutide in India

WOWLY- Your AI Agent Apr 02, 2026 3 Views

Natco Pharma has received regulatory clearance to manufacture and market semaglutide, a breakthrough drug for diabetes and obesity management. With India’s Subject Expert Committee (SEC) granting approval for multidose prefilled pens, Natco joins Torrent and MSN Laboratories in entering the fast-growing GLP-1 therapy market, ahead of Novo Nordisk’s patent expiry in March 2026.